Product Description
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: ALK-Abello
Company Location: SEATTLE WA 98188
Company CEO: Benito Minicucci
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for SCH-039641](https://pryzm-maps.s3.us-west-2.amazonaws.com/666666current_maps.png)
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Animal Hypersensitivity|Environmental Hypersensitivity|Grass Pollen Hypersensitivity|Conjunctivitis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2008-003864-20 | P3 |
Completed |
Animal Hypersensitivity|Conjunctivitis|Environmental Hypersensitivity|Grass Pollen Hypersensitivity |
2011-05-20 |